+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast to 2030- Product Image
Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast to 2030- Product Image
Sale

Viral Vector Manufacturing Market by Vector Type, Workflow, Delivery Method, Technology, Disease Indication, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5613111
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The viral vector manufacturing market is entering a period of elevated opportunity and complexity, shaped by growing demand for gene and cell therapies, evolving regulatory standards, and breakthroughs in manufacturing technologies. For senior decision-makers, understanding the shifting landscape is essential to drive competitive advantage and sustainable growth.

Market Snapshot: Viral Vector Manufacturing Growth Trajectory

The Viral Vector Manufacturing Market grew from USD 9.19 billion in 2024 to USD 11.00 billion in 2025. It is expected to continue growing at a CAGR of 20.03%, reaching USD 27.50 billion by 2030. This substantial growth reflects the acceleration of novel gene and cell therapies that depend on high-grade vector production, making the market a focal point for innovation and strategic investment.

Scope & Segmentation

This comprehensive report offers in-depth coverage of the viral vector manufacturing market’s structure, regional dynamics, technology trends, and application segments.

  • Vector Types: Adenoviral vectors, baculoviral vectors, herpes simplex vectors, lentiviral vectors, plasmid DNA platforms, and retrovirus systems, each with distinct utility in oncology, cell therapies, vaccine development, and inherited disorders.
  • Workflow: Includes downstream processing steps such as formulation and purification, and upstream activities like bioreactors, cell culture systems, and advanced media formulations.
  • Delivery Methods: Covers ex vivo approaches (cell re-infusion, cell transduction) and in vivo options (direct injection, intravenous, oral administration), emphasizing different operational and safety priorities.
  • Technology: Encompasses purification techniques like chromatography and ultrafiltration, as well as transfection methods including chemical-based and electroporation platforms.
  • Disease Indications: Cardiovascular, genetic, infectious, and metabolic disorders, aligning platform selection with evolving clinical needs.
  • Applications: Gene therapy for inherited and oncological disorders, oncolytic virotherapy, gene inactivation, tumor suppressor strategies, and vaccinology targeting cancer, infectious, and zoonotic diseases.
  • End Users: Biotechnology companies, pharmaceutical manufacturers, academic and government research institutions.
  • Regions: Americas (with specific focus on US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (notably UK, Germany, France, Russia, Saudi Arabia, South Africa, and others), and Asia-Pacific (including China, India, Japan, Australia, South Korea, and additional key markets).
  • Key Companies: ABL Inc., Batavia Biosciences B.V., Biovian Oy, Charles River Laboratories, Creative Biogene, Danaher Corporation, FinVector Oy, FUJIFILM Diosynth Biotechnologies, GE HealthCare Technologies, Genezen Laboratories, Kaneka Eurogentec S.A., Lonza Group Ltd., MaxCyte, Merck KGaA, Miltenyi Biotec, Novartis AG, Oxford Biomedica PLC, Sanofi SA, Sirion-Biotech, Spark Therapeutics, Takara Bio, Thermo Fisher Scientific, uniQure N.V., VGXI, Waisman Biomanufacturing, Wuxi AppTec Co., Ltd.

Key Takeaways for Decision-Makers

  • Rapid adoption of single-use technologies and bioreactor automation is facilitating flexible, contamination-resistant production environments across the sector.
  • Digitalization, including process analytical technology and digital twins, is strengthening real-time control over manufacturing quality while enabling predictive optimization.
  • Strategic collaborations between innovators, contract manufacturers, and academic stakeholders are compressing development timelines and expanding access to new vector platforms.
  • Process intensification initiatives—such as perfusion bioreactors and continuous chromatography—support scalability and cost containment despite changing global supply conditions.
  • Diversifying vector portfolios remains essential, with adenoviral and lentiviral vectors addressing distinct clinical needs, and emerging constructs supporting more specialized therapies and vaccines.
  • Regional strategies differ significantly: North America’s mature regulatory and funding climate contrasts Asia-Pacific’s infrastructural investments and Europe’s harmonized public-private initiatives.

Tariff Impact: Navigating Supply Chain Pressures

With US tariffs on raw materials and reagents introduced in 2025, global supply chains are experiencing cost increases and sourcing challenges. Manufacturers are countering these impacts by near-shoring component production, pursuing regional alliances, and investing in process innovations that reduce reliance on tariff-affected inputs. These adjustments aim to protect profit margins and maintain product quality and delivery timelines.

Methodology & Data Sources

This report applies a rigorous methodology, integrating primary interviews with executives and industry experts alongside extensive secondary analysis. Public regulatory documents, patent and corporate filings, peer-reviewed literature, and proprietary databases underpin findings, with scenario modeling and expert panel validation ensuring data integrity and relevance.

Why This Report Matters

  • Provides actionable market segmentation and technology insights to guide investment, capacity expansion, and partnership strategies.
  • Delivers targeted analysis on tariff pressures, supply chain risk mitigation, and technology adoption for informed decision-making.
  • Enables benchmarking against regional and global best practices, supporting strategic planning and organizational resilience.

Conclusion

Viral vector manufacturing is evolving rapidly, shaped by innovation, regulation, and shifting global dynamics. Informed, agile strategies will position organizations to capture growth opportunities while managing risks in this transformative sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing adoption of viral vectors in vaccine production against infectious diseases
5.1.1.2. Growing emphasis on personalized medicine and gene therapy
5.1.1.3. Supportive government initiatives bolstering viral vector manufacturing capabilities globally
5.1.2. Restraints
5.1.2.1. High production costs and inconsistencies in raw materials
5.1.3. Opportunities
5.1.3.1. Enhancement of gene therapy solutions for structural and functional retinal diseases
5.1.3.2. Investment in scalable manufacturing processes for high-volume production of viral vectors
5.1.4. Challenges
5.1.4.1. Complex regulatory landscapes ensuring compliance with varying standards worldwide
5.2. Market Segmentation Analysis
5.2.1. Vector Type: Rising utilization of adenoviral vector in vaccines and gene therapy owing to strong immunogenic profile and ability to infect non-dividing cells
5.2.2. Application: Rising demand for gene therapy for treating inherited disorders and oncological disorders
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Viral Vector Manufacturing Market, by Vector Type
6.1. Introduction
6.2. Adenoviral Vectors
6.3. Baculoviral Vectors
6.4. Herpes Simplex Vectors
6.5. Lentiviral Vectors
6.6. Plasmid DNA
6.7. Retrovirus
7. Viral Vector Manufacturing Market, by Workflow
7.1. Introduction
7.2. Downstream Processing
7.2.1. Formulation
7.2.2. Purification
7.3. Upstream Processing
7.3.1. Bioreactors
7.3.2. Cell Culture Systems
7.3.3. Media Formulations
8. Viral Vector Manufacturing Market, by Delivery Method
8.1. Introduction
8.2. Ex Vivo
8.2.1. Cell Re-infusion
8.2.2. Cell Transduction
8.3. In Vivo
8.3.1. Direct Injection
8.3.2. Intravenous Route
8.3.3. Oral Administration
9. Viral Vector Manufacturing Market, by Technology
9.1. Introduction
9.2. Purification Techniques
9.2.1. Chromatography
9.2.2. Ultrafiltration
9.3. Transfection Methods
9.3.1. Chemical-Based
9.3.2. Electroporation
10. Viral Vector Manufacturing Market, by Disease Indication
10.1. Introduction
10.2. Cardiovascular Diseases
10.3. Genetic Disorders
10.4. Infectious Diseases
10.5. Metabolic Disorders
11. Viral Vector Manufacturing Market, by Application
11.1. Introduction
11.2. Gene Therapy
11.2.1. Inherited Disorders
11.2.2. Oncological Disorders
11.2.3. Single Gene Mutations
11.3. Oncology Research
11.3.1. Gene Inactivation
11.3.2. Oncolytic Virotherapy
11.3.3. Tumor Suppressor Genes
11.4. Vaccinology
11.4.1. Cancer Vaccines
11.4.2. Infectious Diseases
11.4.3. Zoonotic Diseases
12. Viral Vector Manufacturing Market, by End User
12.1. Introduction
12.2. Biotechnology Companies
12.2.1. Large Enterprises
12.2.2. Start-Ups
12.3. Pharmaceutical Companies
12.3.1. Manufacturing
12.3.2. Research and Development
12.4. Research Institutions
12.4.1. Academic Laboratories
12.4.2. Government Labs
13. Americas Viral Vector Manufacturing Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Viral Vector Manufacturing Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Viral Vector Manufacturing Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Scenario Analysis
16.3.1. Abselion secures GBP 1.1 Million to develop next-gen cell platform for viral vector production
16.3.2. Charles River Laboratories launches innovative viral vector tech transfer program to optimize gene therapy development
16.3.3. Andelyn Biosciences partners with FNIH to accelerate gene therapy for rare diseases through innovative AAV manufacturing
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. VIRAL VECTOR MANUFACTURING MARKET MULTI-CURRENCY
FIGURE 2. VIRAL VECTOR MANUFACTURING MARKET MULTI-LANGUAGE
FIGURE 3. VIRAL VECTOR MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 4. VIRAL VECTOR MANUFACTURING MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2024 VS 2030 (%)
FIGURE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 25. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 30. VIRAL VECTOR MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 31. VIRAL VECTOR MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. VIRAL VECTOR MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. VIRAL VECTOR MANUFACTURING MARKET DYNAMICS
TABLE 7. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BACULOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MEDIA FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL RE-INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CELL TRANSDUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DIRECT INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INTRAVENOUS ROUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CHEMICAL-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INHERITED DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY SINGLE GENE MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE INACTIVATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TUMOR SUPPRESSOR GENES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ZOONOTIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY START-UPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ACADEMIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 135. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 136. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 137. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 138. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 139. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 140. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 141. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 142. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 144. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 145. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 146. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 148. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 149. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 150. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 152. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 153. CANADA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 155. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 156. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 157. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 158. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 159. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 160. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 161. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 163. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 164. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 165. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 167. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 168. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 169. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 171. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 172. MEXICO VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES VIRAL VECTOR MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC VIRAL VECTOR MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 232. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 233. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 234. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 235. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 236. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 237. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 238. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 239. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 241. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 242. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 243. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 245. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 246. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 247. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 249. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 250. CHINA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 251. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 252. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 253. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 254. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 255. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 256. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 257. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 258. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 260. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 261. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 262. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 264. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 265. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 266. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 268. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 269. INDIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 290. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 291. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 292. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 293. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 294. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 295. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY IN VIVO, 2018-2030 (USD MILLION)
TABLE 296. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PURIFICATION TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 298. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY TRANSFECTION METHODS, 2018-2030 (USD MILLION)
TABLE 299. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 300. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 302. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY ONCOLOGY RESEARCH, 2018-2030 (USD MILLION)
TABLE 303. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VACCINOLOGY, 2018-2030 (USD MILLION)
TABLE 304. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 306. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 307. JAPAN VIRAL VECTOR MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 310. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 311. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
TABLE 312. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 313. MALAYSIA VIRAL VECTOR MANUFACTURING MARKET SIZE, BY EX VIVO, 2018-2030 (USD MILLION)
TABLE 314. MALAYSIA VIRAL VECTOR MANUFACTUR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Viral Vector Manufacturing market report include:
  • ABL Inc.
  • Batavia Biosciences B.V. by CJ Cheiljedang
  • Biovian Oy
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Danaher Corporation
  • FinVector Oy
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • GE HealthCare Technologies, Inc.
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec S.A.
  • Lonza Group Ltd.
  • MaxCyte, Inc.
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Novartis AG
  • Oxford Biomedica PLC
  • Sanofi SA
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure N.V.
  • VGXI, Inc. by GeneOne Life Science
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11 Billion
Forecasted Market Value ( USD ) by 2030 $ 27.5 Billion
Compound Annual Growth Rate20.0%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Viral Vectors Market by Vector Type, Application, Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast to 2030 - Product Image

Viral Vectors Market by Vector Type, Application, Therapeutic Area, End User, Production Stage, Production Scale - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Viral Vector & Plasmid DNA Manufacturing Market by Service Type, Product Type, Application, Technology Platform, Scale, End User - Global Forecast to 2030 - Product Image

Viral Vector & Plasmid DNA Manufacturing Market by Service Type, Product Type, Application, Technology Platform, Scale, End User - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region - Product Image

Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, Type of Manufacturer and Geographical Region

  • Report
  • 768 Pages
  • Global
From
Viral Vector Manufacturing Market Size, Share, Trends and Forecast by Type, Disease, Application, End User, and Region, 2025-2033 - Product Image

Viral Vector Manufacturing Market Size, Share, Trends and Forecast by Type, Disease, Application, End User, and Region, 2025-2033

  • Report
  • 146 Pages
  • Global
From
Viral Vector Manufacturing - Global Strategic Business Report - Product Image

Viral Vector Manufacturing - Global Strategic Business Report

  • Report
  • 402 Pages
  • Global
From

About the Viral Vector Manufacturing Market

The Viral Vector Manufacturing market is a subset of the genomics industry that focuses on the production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, cystic fibrosis, and hemophilia. The Viral Vector Manufacturing market is highly competitive, with a number of companies offering a range of services. These services include vector design, vector production, and vector characterization. Companies also provide custom services to meet the specific needs of their customers. Some of the major players in the Viral Vector Manufacturing market include Lonza, Thermo Fisher Scientific, Merck KGaA, and Oxford BioMedica. These companies offer a range of services, from vector design to vector production and characterization. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.